Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.59 |
| ▸ | THRA | P10827 | 6/20 | 0.59 |
| ▸ | PPARG | P37231 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | TTR | P02766 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | RXRA | P19793 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417806 | 1.00 | THRB (0.59) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL10780803 | 1.00 | THRB (0.59) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL18558000 | 0.96 | THRB (0.55) | THRBTHRAPPARGMEN1KMT2A | |
| Ethylenediamine SCHEMBL11090366 | 0.96 | THRB (0.57) | THRBTHRAPPARGMEN1KMT2A | |
| Putrescine SCHEMBL11092650 | 0.94 | THRB (0.55) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL10780866 | 0.93 | THRB (0.57) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL12808939 | 0.91 | THRB (0.56) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL13952218 | 0.91 | ACE (0.50) | THRBTHRAPPARGMEN1KMT2A | |
| SCHEMBL21243772 | 0.91 | ACE (0.58) | PPARGITGB3ITGAVACEITGA2B | |
| SCHEMBL5160323 | 0.91 | ACE (0.58) | PPARGITGB3ITGAVACEITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9839614-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839614-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839614-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| WO-2008051291-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | ORDWAY RESEARCH INSTITUTE (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051291-A2 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | ORDWAY RESEARCH INSTITUTE (US) | 2008-05-02 | — | — | WO | disclosed |
| US-7271009-B1 | Multi-analyte diagnostic test for thyroid disorders | BIO-RAD LABORATORIES, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070178604-A1 | Multi-analyte diagnostic test for thyroid disorders | BIO-RAD LABORATORIES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070178604-A1 | Multi-analyte diagnostic test for thyroid disorders | BIO-RAD LABORATORIES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| EP-1272855-B1 | MULTI-ANALYTE DIAGNOSTIC TEST FOR THYROID DISORDERS | BIO RAD LABORATORIES (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20070099841-A1 | Prodrugs of T3 and T4 with enhanced bioavailability | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099841-A1 | Prodrugs of T3 and T4 with enhanced bioavailability | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2007030577-A2 | PRODRUGS OF T3 AND T4 WITH ENHANCED BIOAVAILABILITY | SHIRE LLC (US) | 2007-03-15 | — | — | WO | disclosed |
| US-4786591-A | HETEROGENEOUS IMMUNOASSAY | BOEHRINGER MANNHEIM GMBH (DE) | 1988-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099841-A1 | Prodrugs of T3 and T4 with enhanced bioavailability | THRA, THRB, SLC7A1 | THRB 2/4885THRA 1/4885PPARG 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.